Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease

This publication has 49 references indexed in Scilit:

• Potassium channels and erectile dysfunction
  Vascular Pharmacology, 2002
• The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil
  International Journal Of Impotence Research, 2001
• Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure
  The FASEB Journal, 2001
• Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue
  Urology, 2000
• Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro
  The American Journal of Cardiology, 1999
• Phosphodiesterase III and V Inhibitors on Pulmonary Artery from Pulmonary Hypertensive Rats: Differences Between Early and Established Pulmonary Hypertension
  Journal of Cardiovascular Pharmacology, 1998
• Oral Sildenafil in the Treatment of Erectile Dysfunction
  New England Journal of Medicine, 1998
• Fortnightly review: Update on male erectile dysfunction
  BMJ, 1998
• Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms
  Physiological Reviews, 1995
• Cl- current activation in choroid plexus epithelial cells involves a G protein and protein kinase A
  American Journal of Physiology-Cell Physiology, 1994